Hepatitis B virus RNA-directed DNA polymerase (HBV Pol) (HBV Pol)

The Hepatitis B virus (HBV) RNA-directed DNA polymerase, also known as the P protein, is a multifunctional enzyme essential for the replication of the HBV genome (UniProt P03156). It functions as a reverse transcriptase, converting pregenomic RNA into negative-strand DNA, and subsequently acts as a DNA-directed DNA polymerase to synthesize the positive-strand DNA (PubMed: 15843901). This enzyme is the primary therapeutic target for chronic hepatitis B, as its inhibition directly prevents the formation of new viral particles. Entecavir, a guanosine nucleoside analogue, is phosphorylated intracellularly to its active form, entecavir triphosphate, which potently inhibits the HBV polymerase (FDA: Baraclude Label). Entecavir triphosphate competes with the natural substrate, deoxyguanosine triphosphate, to block three distinct stages of viral replication: base priming, reverse transcription, and DNA strand synthesis (PubChem CID 135398508). By suppressing viral replication, drugs targeting this enzyme reduce the risk of liver cirrhosis and hepatocellular carcinoma (StatPearls: Hepatitis B). Long-term suppression of the polymerase activity is the cornerstone of modern HBV therapy, although the emergence of resistance mutations remains a significant clinical challenge (PubMed: 19128055).

Other names

P proteinHepatitis B virus polymeraseHBV DNA polymeraseReverse transcriptaseHBV Pol

Entecavir triphosphate inhibits the HBV polymerase by competing with the natural substrate deoxyguanosine triphosphate. This competition results in the inhibition of three specific viral activities: (1) base priming of the HBV DNA polymerase, (2) reverse transcription of the negative strand DNA from the pregenomic messenger RNA, and (3) synthesis of the positive strand HBV DNA (FDA: Baraclude Label; PubChem CID 135398508).